Blueprint Medicines

lung cancer
Biotech

Blueprint drops lung cancer programs after seeing early data

Blueprint is dropping two non-small cell lung cancer programs in response to early clinical data on the EGFR tyrosine kinase inhibitors.
Nick Paul Taylor Jan 9, 2024 9:22am
permit blueprint approved rubber stamped yes check

Blueprint's solid tumor med permitted to resume trial

Mar 29, 2023 5:00am
Stock image of blueprints and a hard hat

Blueprint's solid tumor med slapped with partial clinical hold

Feb 10, 2023 10:30am
Resist resistance fight against cancer arrows out tumor immunotherapy

AACR: Blueprint wants to make resistance to Tagrisso futile

Apr 8, 2022 1:00pm
blueprint

A $632M protein degrader Blueprint for a nascent Vant biotech

Feb 28, 2022 8:45am
concept of chess board with letters MA

Blueprint drops $250M on Lengo for preclinical lung cancer med

Nov 29, 2021 10:20am